Assessments at baseline and days 14, 42, and 84 after infliximab treatment42
| Parameter | Baseline | Day 14 | Day 42 | Day 84 |
|---|---|---|---|---|
| Values are the median; *p≤0.05; **p≤0.01; ***p≤0.001. | ||||
| Global disease activity assessments (n=21) | ||||
| Patient (0–100) | 57 | 23*** | 11*** | 10*** |
| Physician (0–100) | 57 | 23*** | 11*** | 10*** |
| Axial assessments (n=11) | ||||
| Morning stiffness (min) | 90 | 15** | 10** | 5** |
| BASDAI (0–100) | 62.4 | 18.3** | 9.5** | 11.3** |
| BASFAI (0–100) | 77.4 | 29.4** | 13.1** | 22.3** |
| Spinal pain (0–3) | 2 | 1 | 0* | 0* |
| Peripheral assessments (n=18) | ||||
| Morning stiffness (min) | 90 | 5*** | 10** | 5*** |
| Tender joint count (0–68) | 6 | 2*** | 0*** | 0*** |
| Swollen joint count (0–66) | 3.5 | 1*** | 0*** | 0*** |